Lorena Rocha Ayres1, André de Oliveira Baldoni, Anna Paula de Sá Borges, Leonardo Régis Leira Pereira. 1. Departamento de Ciências Farmacêuticas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Centro de Pesquisa em Assistência Farmacêutica e Farmácia Clínica (CPAFF), Universidade de São Paulo, Avenida do Café, s/no., Campus Universitário da USP, Ribeirão Preto, SP, 14040-903, Brazil, lorenaayres@hotmail.com.
Abstract
BACKGROUND: Oral treatment in women with breast cancer has been increasingly used. However, a potentially negative side of oral medication is poor patient adherence and/or discontinuation, which reduces the treatment effectiveness, accelerating progression of the disease and reducing the patient survival rate. AIM OF THE REVIEW: To compare the rates of adherence and/or discontinuation and the methodologies used to assess these outcomes. It was conducted an integrative review of original articles published from 2000 to 2012, in which their primary outcome was to quantify medication adherence and/or discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. METHODS: Original studies were searched in the PubMed/MEDLINE, Scopus, Embase and SciELO databases. The Medical Subject Heading was used to define descriptors. The descriptor "breast neoplasms" was used in all combinations. Each of the descriptors "medication adherence" and "patient compliance" were combined with each of the following descriptors "tamoxifen", "aromatase inhibitors", "selective estrogen receptor modulators", or the terms "letrozole", "anastrozole", and "exemestane". RESULTS: Twenty-four original articles were included. Our study showed a wide range of adherence and discontinuation rates, ranging from 45-95.7 and 12-73 %, respectively. Regarding the methodological development of the selected articles, a high prevalence (87.5 %) of prospective and/or retrospective longitudinal studies was found. In addition, there was a high prevalence of studies using a database (70.8 %). Among some of the studies, it was shown that patient adherence to hormonal therapy gradually reduces, while discontinuation increases during the treatment. CONCLUSIONS: It was observed a great diversity among rates of adherence and/or discontinuation of hormonal therapy for breast cancer, which may be due to a lack of methodology standardization. Therefore, adequate and validated methods to ensure reliability of the results and allow comparison in the literature are needed. Furthermore, adherence decreases and discontinuation increases over time, suggesting the need for patient continuous education and a pharmacotherapeutic follow up by health professionals to improve these clinical outcomes.
BACKGROUND: Oral treatment in women with breast cancer has been increasingly used. However, a potentially negative side of oral medication is poor patient adherence and/or discontinuation, which reduces the treatment effectiveness, accelerating progression of the disease and reducing the patient survival rate. AIM OF THE REVIEW: To compare the rates of adherence and/or discontinuation and the methodologies used to assess these outcomes. It was conducted an integrative review of original articles published from 2000 to 2012, in which their primary outcome was to quantify medication adherence and/or discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. METHODS: Original studies were searched in the PubMed/MEDLINE, Scopus, Embase and SciELO databases. The Medical Subject Heading was used to define descriptors. The descriptor "breast neoplasms" was used in all combinations. Each of the descriptors "medication adherence" and "patient compliance" were combined with each of the following descriptors "tamoxifen", "aromatase inhibitors", "selective estrogen receptor modulators", or the terms "letrozole", "anastrozole", and "exemestane". RESULTS: Twenty-four original articles were included. Our study showed a wide range of adherence and discontinuation rates, ranging from 45-95.7 and 12-73 %, respectively. Regarding the methodological development of the selected articles, a high prevalence (87.5 %) of prospective and/or retrospective longitudinal studies was found. In addition, there was a high prevalence of studies using a database (70.8 %). Among some of the studies, it was shown that patient adherence to hormonal therapy gradually reduces, while discontinuation increases during the treatment. CONCLUSIONS: It was observed a great diversity among rates of adherence and/or discontinuation of hormonal therapy for breast cancer, which may be due to a lack of methodology standardization. Therefore, adequate and validated methods to ensure reliability of the results and allow comparison in the literature are needed. Furthermore, adherence decreases and discontinuation increases over time, suggesting the need for patient continuous education and a pharmacotherapeutic follow up by health professionals to improve these clinical outcomes.
Authors: Gillian C Hall; Brian Sauer; Alison Bourke; Jeffrey S Brown; Matthew W Reynolds; Robert LoCasale; Robert Lo Casale Journal: Pharmacoepidemiol Drug Saf Date: 2011-11-08 Impact factor: 2.890
Authors: C Cluze; D Rey; L Huiart; M K BenDiane; A D Bouhnik; C Berenger; M P Carrieri; R Giorgi Journal: Ann Oncol Date: 2011-07-25 Impact factor: 32.976
Authors: Aliza K Fink; Jerry Gurwitz; William Rakowski; Edward Guadagnoli; Rebecca A Silliman Journal: J Clin Oncol Date: 2004-08-15 Impact factor: 44.544
Authors: John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: Alessio Fioravanti; Giuseppe Fico; Dario Salvi; Rebeca I García-Betances; Maria Teresa Arredondo Journal: Med Biol Eng Comput Date: 2015-01-07 Impact factor: 2.602
Authors: Gretchen Kimmick; Sara N Edmond; Hayden B Bosworth; Jeffrey Peppercorn; Paul K Marcom; Kimberly Blackwell; Francis J Keefe; Rebecca A Shelby Journal: Breast Date: 2015-07-16 Impact factor: 4.380
Authors: Alejandra Hurtado-de-Mendoza; Mark L Cabling; Tania Lobo; Chiranjeev Dash; Vanessa B Sheppard Journal: Clin Breast Cancer Date: 2016-03-31 Impact factor: 3.225
Authors: Xi Tan; Fabian Camacho; Vincent D Marshall; Joseph Donohoe; Roger T Anderson; Rajesh Balkrishnan Journal: Res Social Adm Pharm Date: 2016-08-25
Authors: Kea Turner; Cleo A Samuel; Heidi As Donovan; Ellen Beckjord; Alexandra Cardy; Mary Amanda Dew; G J van Londen Journal: Support Care Cancer Date: 2016-11-18 Impact factor: 3.603
Authors: Cleo A Samuel; Kea Turner; Heidi A S Donovan; Ellen Beckjord; Alexandra Cardy; Mary Amanda Dew; G J van Londen Journal: Support Care Cancer Date: 2017-07-06 Impact factor: 3.603
Authors: Christian Felix Reibold; Wakuma Tariku; Pia Eber-Schulz; Sefonias Getachew; Adamu Addisie; Susanne Unverzagt; Andreas Wienke; Steffen Hauptmann; Claudia Wickenhauser; Martina Vetter; Ahmedin Jemal; Christoph Thomssen; Eva Johanna Kantelhardt Journal: Breast Care (Basel) Date: 2021-01-15 Impact factor: 2.860
Authors: Alejandra Hurtado de Mendoza; Mark Cabling; Asma Dilawari; Jeanine W Turner; Nicole Fernández; Alesha Henderson; Qi Zhu; Sara Gómez; Vanessa B Sheppard Journal: Health Technol (Berl) Date: 2018-10-05
Authors: Xi Tan; Vincent D Marshall; Roger T Anderson; Joseph Donohoe; Fabian Camacho; Rajesh Balkrishnan Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889